. home.aspx



AZ and Novoheart collaborate on ‘heart in a jar’, to develop new HF drugs

November 27, 2019 / Richard Staines

Stem cell biotech Novoheart is to collaborate with AstraZeneca to develop a “heart in a jar” that will be used to help develop new heart failure drugs. The companies will work on the world’s first human-specific in vitro functional model of heart failure with preserved ejection fraction (HFpEF). HFpEF is a common condition especially among the elderly and in women, with reported prevalence approaching 10% in women aged over 80. AZ has already made inroads into heart failure with its Farxiga, approved by the FDA last month to reduce chances of hospitalisations for heart failure in adults with type 2 diabetes and other cardiovascular risks. The FDA has granted Fast Track designation for Farxiga to reduce the risk of CV death, or the worsening of heart failure in adults with heart failure with reduced ejection fraction (HFrEF) or HFpEF based on the Phase 3 DAPA-HF and DELIVER trials. Boehringer and Eli Lilly are developing Jardiance in heart failure, including the preser...